Gene "CD81"
Found 2 records
Gene information
Gene symbol:
CD81
See related:
Ensembl: ENSG00000110651, Gene ID: 975
Additive variants :
Undetected
Genetic interaction partners
No data
Modifier statisitcs
Record:
2 
Disorder:
1 
Vriant:
1 
Reference:
1 
Effect type:
Expressivity(2)  
Modifier effect:
Altered HCV risk(1) ,Altered HCV risk and altered levels of high-density lipoprotein cholesterol(1)  
Details：
  • Variant 1:
    CD81:c.67-1543C>T
    Gene:
    CD81
    Genomic location:
    chr11:2410099
    dbSNP ID:
    rs708564
    Target disease:
    Hepatitis C(DOID_1883)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered HCV risk and altered levels of high-density lipoprotein cholesterol 
    Evidence:
    HDL-c; OR=0.71, 95% CI: 0.52-0.96 
    Effect:
    Homozygous CD81 rs708564 TT may be a genetic modifier for avoiding HCV infection
    Reference:
    PMID25934191
    Title:
    CD81 and CLDN1 polymorphisms and hepatitis C virus infection susceptibility: a case control study.
    Species studied:
    Human
    Abstract:
    CD81 and CLDN1 interact to form a CD81-CLDN1 co-receptor complex that is crucial in hepatitis C virus (HCV) entry. Variations in the two genes were shown to influence immunological functions; therefore, we hypothesized that polymorphisms in these genes may contribute to HCV susceptibility. A case-control study consisting of 461 patients and 461 controls was conducted to explore the associations between CD81 rs708564 and CLDN1 rs893051 and HCV susceptibility in a Chinese population. We found a decreased HCV risk associated with the CD81 rs708564 TT (odds ratio (OR) = 0.66, 95% CI = 0.44-0.98) genotype. The gene-gene interaction between CD81 and CLDN1 polymorphisms also decreased HCV risk in a joint multiplicative manner (OR for the presence of both CD81 rs708564 TT and CLDN1 rs893051 GG genotypes = 0.59, 95% CI = 0.36-0.97). Furthermore, the CD81 rs708564 TT genotype conferred a more pronounced decrease in HCV susceptibility in combination with lower levels of high-density lipoprotein cholesterol (HDL-C; OR = 0.71, 95% CI = 0.52-0.96), and higher levels of low-density lipoprotein cholesterol (OR = 0.24, 95% CI = 0.09-0.65). We also observed a decreased HCV susceptibility in individuals with higher HDL-C levels who carried the CLDN1 rs893051 G/C genotype. These findings suggest that homozygous CD81 rs708564 TT may be a genetic modifier for avoiding HCV infection whether as a sole single nucleotide polymorphism or combined with the CLDN1 rs893051 GG genotype, and this effect is associated with serum levels of lipoprotein.
  • Variant 2:
    CD81:c.67-1543C>T
    Gene:
    CD81
    Genomic location:
    chr11:2410099
    dbSNP ID:
    rs708564
    Target disease:
    Hepatitis C(DOID_1883)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered HCV risk 
    Evidence:
    OR=0.66, 95% CI: 0.44-0.98 
    Effect:
    Homozygous CD81 rs708564 TT may be a genetic modifier for avoiding HCV infection
    Reference:
    PMID25934191
    Title:
    CD81 and CLDN1 polymorphisms and hepatitis C virus infection susceptibility: a case control study.
    Species studied:
    Human
    Abstract:
    CD81 and CLDN1 interact to form a CD81-CLDN1 co-receptor complex that is crucial in hepatitis C virus (HCV) entry. Variations in the two genes were shown to influence immunological functions; therefore, we hypothesized that polymorphisms in these genes may contribute to HCV susceptibility. A case-control study consisting of 461 patients and 461 controls was conducted to explore the associations between CD81 rs708564 and CLDN1 rs893051 and HCV susceptibility in a Chinese population. We found a decreased HCV risk associated with the CD81 rs708564 TT (odds ratio (OR) = 0.66, 95% CI = 0.44-0.98) genotype. The gene-gene interaction between CD81 and CLDN1 polymorphisms also decreased HCV risk in a joint multiplicative manner (OR for the presence of both CD81 rs708564 TT and CLDN1 rs893051 GG genotypes = 0.59, 95% CI = 0.36-0.97). Furthermore, the CD81 rs708564 TT genotype conferred a more pronounced decrease in HCV susceptibility in combination with lower levels of high-density lipoprotein cholesterol (HDL-C; OR = 0.71, 95% CI = 0.52-0.96), and higher levels of low-density lipoprotein cholesterol (OR = 0.24, 95% CI = 0.09-0.65). We also observed a decreased HCV susceptibility in individuals with higher HDL-C levels who carried the CLDN1 rs893051 G/C genotype. These findings suggest that homozygous CD81 rs708564 TT may be a genetic modifier for avoiding HCV infection whether as a sole single nucleotide polymorphism or combined with the CLDN1 rs893051 GG genotype, and this effect is associated with serum levels of lipoprotein.